Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Tabrecta Is First Treatment For NSCLC With METex14 Mutation

Executive Summary

The US FDA granted an accelerated approval for the lung cancer treatment targeting a mutation found in only about 4,000-5,000 NSCLC patients in the US each year.

You may also be interested in...



Foundation Medicine Obtains FDA Approval For Non Small Cell Lung Cancer Companion Diagnostic

Foundation Medicine and Novartis’ commercial partnership has achieved another success as Foudation’s Liquid CDx is approved.

Japan Nods Include Global Firsts For Duvroq, Vafseo And First Local Biosimilar Humira

Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.

Commercial Models Shifting As Pharma Mulls Digital-First Launches

Pharma is assessing digital-first launch strategies amid COVID-19 while a resizing of sales forces and the emergence of "digital orchestrators" may also be in store, the co-founder of healthcare solutions provider Indegene tells Scrip.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel